Projet de thèse en Pharmaco-épidémiologie - Option pharmaco-épidémiologie, pharmaco-vigilance
Sous la direction de Albert Figueras et de Francesco Salvo.
Thèses en préparation à Bordeaux , dans le cadre de École doctorale Sociétés, politique, santé publique (Bordeaux) , en partenariat avec Bordeaux Research Center for Population Health (laboratoire) et de T9 - Médicament et santé des populations (equipe de recherche) depuis le 30-11-2013 .
L'objectif de ce projet doctoral est d'avoir un aperçu de la situation de l'usage des médicaments au Pakistan et de mettre en évidence la nécessité d'un bon système de pharmacovigilance et de pharmacoépidémiologie.
Analysis of the medicines panorama in Pakistan
The brief activities over the last 8 months have been briefly described below. 1. General description of medicines consumed in Pakistan: This topic includes two studies with the a. First one focusing on studying the overall market width of medicines with fixed dose combinations and their irrationalities. b. Second study from the same topic includes focus on cephalosporin's use in Pakistan. Progress: The data on Medicines Marketed with Registrations from Drug Regulatory Authority of Pakistan & Cephalosporin Use was recollected from IMS until Feb 2018 and is currently being analyzed for the study objectives. The background have been written for both studies. 2. Survey on Type 1 Diabetes guidelines in Pakistan Progress: The data (semi structured questionnaire) has already been collected in collaboration with the local diabetic institute from the 10 medical units across Pakistan treating type I diabetes patients. Preliminary write up completed (pending review and further direction from the supervisor) 3. Studying the Adverse drug events in the Primary, Secondary and Tertiary Care hospitals in Pakistan Progress: The 20 item questionnaire has been re-administered to more than 2500 health care professionals across Pakistan. The initial response rate was very low so it's currently being administered through a local person from various institutes to achieve the 20-25 percent response rate for any meaningful outcome. 4. Studying reported results from Pakistan's first Drug Poison Information Centre & Pharmacovigilance Centre Progress: Data was analyzed from the calls received (during 2014-2018) at the center, but there were lot of missing information and to identify why these data was useless to talk of real pharmacovigilance, Prof Albert proposed of doing an intervention involving training and the recollection of data afterwards, but due to financial constraints this has not been initiated yet. 5. Training in a European Pharmaceutical company focusing PSUSA procedure: Progress: I am currently training since May 2018 at Grünenthal Pharma, Germany where I am working with cross functional teams with a focus on a PSUSA procedure for an opioid painkiller. I am also part of the Benefit Risk Team for this product. Following studies were abandoned due to complexity and difficulty in data acquisition. 1. Regional differences in Drug prescription patterns 2. Studying adverse drug reactions associated to medicines use 3. What is prescribed and what is consumed I can also share the details of the seminar on Pharmacovigilance that I help arrange in Lahore, Pakistan where Prof. Albert's recorded lecture was played along with other lectures I did during the years 2014-2015 on patient safety (also focusing on Medicines).